Check for updates

OPEN ACCESS

EDITED BY Mario Bernardo-Filho, Rio de Janeiro State University, Brazil

REVIEWED BY

Danúbia Da Cunha De Sá Caputo, Rio de Janeiro State University, Brazil Antonio Roberto Zamunér, Catholic University of Maule, Chile

*CORRESPONDENCE

Xiaoyan Zheng ⊠ zhengxiaoyan181@126.com Jihua Zou ⊠ zoujihua@i.smu.edu.cn Qing Zeng ⊠ zengqingyang203@126.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Neurorehabilitation, a section of the journal Frontiers in Neurology

RECEIVED 20 October 2022 ACCEPTED 04 January 2023 PUBLISHED 26 January 2023

CITATION

Zhang Q, Zheng S, Li S, Zeng Y, Chen L, Li G, Li S, He L, Chen S, Zheng X, Zou J and Zeng Q (2023) Efficacy and safety of whole-body vibration therapy for post-stroke spasticity: A systematic review and meta-analysis. *Front. Neurol.* 14:1074922. doi: 10.3389/fneur.2023.1074922

COPYRIGHT

© 2023 Zhang, Zheng, Li, Zeng, Chen, Li, Li, He, Chen, Zheng, Zou and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Efficacy and safety of whole-body vibration therapy for post-stroke spasticity: A systematic review and meta-analysis

Qi Zhang^{1,2†}, Shuqi Zheng^{1,2†}, Shuiyan Li^{1,2†}, Yuting Zeng², Ling Chen², Gege Li^{1,2}, Shilin Li^{1,2}, Longlong He^{1,2}, Shuping Chen^{1,2}, Xiaoyan Zheng^{1*}, Jihua Zou^{1,2,3*} and Qing Zeng^{1,2*}

¹School of Rehabilitation Sciences, Southern Medical University, Guangzhou, China, ²Department of Rehabilitation Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China, ³Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong, China

Background: One of the main objectives of stroke rehabilitation is to alleviate post-stroke spasticity. Over the recent years, many studies have explored the potential benefits of whole-body vibration (WBV) treatment for post-stroke spasticity, but it is still controversial.

Objective: The current study aims to assess the efficacy and safety of WBV for post-stroke spasticity and determine the appropriate application situation.

Methods: From their establishment until August 2022, the following databases were searched: PubMed, Web of Science, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Medline, China National Knowledge Infrastructure (CNKI), and Wanfang. Only randomized controlled trials (RCTs) that were published in either English or Chinese were taken into consideration. We independently filtered the research, gathered the data from the studies, and evaluated the research quality (Cochrane RoB tool) and the overall evidence quality (GRADE). Rev Man 5.4 software was utilized to conduct statistical analysis.

Results: In this analysis, 11 RCTs with 475 patients that reported on the effectiveness of WBV therapy for post-stroke spasticity were taken into account. Compared to the control groups, the results revealed that WBV combined with conventional rehabilitation at a vibration frequency lower than 20 Hz (SMD = -0.58, 95% CI: -0.98 to -0.19, P = 0.004) was more effective in relieving upper (SMD = -0.53, 95% CI: -1.04 to 0.03, P = 0.03) and lower limb spasticity (SMD = -0.21, 95% CI: -0.40 to -0.01, P = 0.04); similarly, it was superior for patients aged under 60 years (SMD = -0.41, 95% CI: -0.66 to -0.17, P = 0.0008) with acute and subacute stroke (SMD = -0.39, 95% CI: -0.68 to -0.09, P = 0.01). The valid vibration for reducing spasticity was found to last for 10 min (SMD = -0.41, 95% CI: -0.75 to -0.07, P = 0.02). None of the included studies revealed any serious adverse impact.

Conclusion: Moderate-quality evidence demonstrated when WBV was used as an adjuvant, vibration <20 Hz for 10 min was effective and secure in treating upper and lower limb spasticity in patients with acute and subacute stroke under the age of 60 years.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022293951.

KEYWORDS

whole body vibration therapy, stroke, muscle spasticity, rehabilitation, meta-analysis

1. Introduction

Throughout the world, stroke is indeed the second leading cause of death and the third leading cause of disability (1). According to statistics, about 5.5 million people die from stroke every year, and the risk of stroke in adults is as high as 24.9% (2). As of 2019, China ranked first in stroke incidence globally, with \sim 17 million people over 40 years of age affected by stroke (2). Spasticity is the most frequent after-stroke consequence, affecting about 40% of patients within days or weeks, and resulting in adverse effects, such as pain, immobility, and muscular contracture, which severely reduce the quality of life (3). Direct finance due to post-stroke spasticity (such as hospitalization, drugs, and health professional services) is about four times more than those who do not have spasticity (4). Thus, spasticity management is an essential component of stroke rehabilitation.

Spasticity can be treated in various ways, such as by administering botulinum toxin injections (5), which is considered the most widely used local treatment of spasticity. Rehabilitation interventions such as stretching of the muscles (5), aquatic exercise (6, 7), mirror therapy (8, 9), ultrasound therapy (10), electrical stimulation (11), and extracorporeal shock wave therapy (12) have also been shown to be useful. Recently, whole-body vibration (WBV) was suggested as a potential therapeutic approach to address spasticity in stroke survivors (13, 14). WBV was recognized as a non-invasive, easily accepted and operated, and well-tolerated technique in which an individual stands on a vibratory board that emits sinusoidal oscillations through the feet to the entire body (15).

Several possible mechanisms have been proposed to explain decreased post-stroke spasticity during exposure to WBV. One proposed mechanism (16) hypothesized that WBV may suppress the synaptic transmission between Ia afferent and motor neurons by inducing presynaptic inhibition, then inhibiting the excitation of spastic muscles, thereby reducing muscle tension. Another way in which vibration has this effect was through the "busy hypothesis," in which the Ia discharge becomes locked to vibration and was subsequently unable to accurately convey the stretchinduced volley due to the entrained action potentials and the high vibration frequency in the Ia fibers (17). Nevertheless, the mechanism of action on spasticity is complicated, and the straightforward monosynaptic reflex or a single route cannot fully account for the anti-spasticity effect of WBV. Many transcranial magnetic stimulation studies (18-20) have demonstrated that WBV also has an impact on the brain's central nervous system. By altering the brain's central nervous system or reducing spinal cord excitability, spasticity of the affected lower limb may alleviate (21). Miyara et al. (22) found that WBV could increase cortical excitability by functional near-infrared spectroscopy. Thus, WBV is thought to be a potential approach for treating spasticity in patients with stroke.

Despite some randomized controlled experiments claiming that WBV reduces post-stroke spasticity (23–25), some other researchers reported it was not observed a benefit of WBV in reducing muscular spasticity (26). Therefore, how WBV impacts post-stroke spasticity is still a debate. This study aims to compile randomized controlled studies that have already been published, analyze the efficacy and safety of WBV systematically, and offer more thorough and rigorous proof for the application of WBV to treat post-stroke spasticity.

2. Methods

This meta-analysis was performed in accordance with the PRISMA guidelines (27). The protocol has a PROSPERO registration (registration code CRD42022293951). Every study was based on previously published research; therefore, neither written consent nor ethical clearance was required.

2.1. Eligibility criteria

The following eligibility requirements have to be satisfied for an original study to be taken into account in our meta-analysis in accordance with the PICOS recommendation (28).

(1) Study types: English or Chinese-language RCTs. (2) Participants types: The population of interest included patients with a diagnosis of post-stroke spasticity and those who give consent to WBV treatment. (3) Interventions: control subjects received sham vibration or identical interventions in both groups, whereas those in the experimental class received WBV or WBV in addition to other therapy (where WBV was an add-on in one group) more than one session. (4) Outcomes: In all included trials, to gauge the degree of spasticity, the Modified Ashworth Scale (MAS) was applied. The outcome measures included those adverse effects that patients experienced during the follow-up time. No distinction was made between outcome data provided as a primary or secondary variable.

2.2. Search strategy

According to the PRISMA guidelines and PICOS design, two reviewers (QZh and SYL) independently carried out a thorough literature search of the PubMed (from 1996), Web of Science (from 1997), Embase (from 1980), Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, latest issue), Medline (from 1948), China National Knowledge Infrastructure (CNKI) (from 1999), and Wanfang (from 2001) for published researches in English or Chinese on WBV for post-stroke spasticity from inception to August 2022. We combined free-text terms with regulated vocabulary (i.e., medical subject headings) as our search approach. The keywords used for searching included WBV, WBVT, vibration training, wholebody vibration, stroke, cerebrovascular accident, brain vascular accident, cerebrovascular strokes, muscle spasticity, spastic, muscle spasm, and muscular spasm. Only English and Chinese were the available languages. In order to satisfy each database's unique requirements, search strategies were changed. The PubMed search approach is shown in Supplementary Figure S1. In addition, we carefully looked over the retrieved publications' reference lists in an effort to find more pertinent studies.

2.3. Literature selection


Two reviewers, YZ and LC, carried out the search strategy and retrieved the abstracts of pertinent publications. The software Endnote X9 was then used to import all of the publications, and duplicate publications were eliminated. After examining the article titles, abstracts, and entire texts, we independently obtained the publications that matched the inclusion and exclusion criteria. Conflicts over which studies to include or exclude were settled through consensus discussions between YZ and LC or through consulting another reviewer (GL).

2.4. Data extraction

YZ and LC separately extracted data from the included randomized clinical trials. According to the recommendations for WBV intervention reporting (29), we extracted and cross-checked the vibration parameters (frequency, amplitude, and duration), protocol characteristics (intervention methods, spasticity sites, positions, follow-up time, etc.), adverse effects, initial author, the publication year, mean age, and course of a stroke. A third researcher (GL) was consulted for any inconsistent data.

2.5. Risk of bias assessment

Using the Cochrane Risk of Bias (RoB) methodology (30), two reviewers evaluated the methodological quality of all included publications. The following domains were evaluated: attrition prejudice (incomplete outcome data), detecting bias (blinding of outcome evaluation), selection bias (random sequence generation and allocation concealment), performance bias (blinding of



Included study	Year	n (experiment)	n (control)	Age/mean (SD)	Spasticity sites
Liao et al. (41)	2016	56	28	61.2 (9.2)/59.8 (9.1)	Lower limb
Lee et al. (39)	2016	15	15	59.2 (7.72)/60.24 (6.73)	Upper limb
Pang et al. (13)	2013	41	41	57.3/57.4	Lower limb
Alp et al. (23)	2018	10	11	61.2 (11.043)/62.91 (8.154)	Lower limb
Brogårdh et al. (26)	2012	16	15	61.3 (8.5)/63 (5.8)	Lower limb
Hwang (42)	2018	9	9	66 (5.77)/70.25 (2.07)	Lower limb
Wang et al. (43)	2018	17	16	48.35 (6.87)/49.17 (7.33)	Upper limb
Li et al. (40)	2014	23	22	49.23 (11.31)/47.43 (11.39)	Lower limb
Wei (44)	2019	20	21	57.25 (7.97)/58.1 (8.49)	Lower limb
He (38)	2020	20	20	54.25 (9.22)/59.9 (7.62)	Lower limb
Xiao et al. (37)	2022	25	25	63.53 (5.26)/63.62 (4.21)	Lower limb

TABLE 1 General characteristics of the studies.

participants and staff), and reporting bias (selective reporting) (31). Three levels of outcomes (low risk, high risk, and unclear) from the evaluation were established (30). In addition, the discrepancies were cleared out by intragroup conversations and by getting in touch with the authors to clarify specifics with the third-party arbitrator.

2.6. Level of evidence

To evaluate the overall evidence quality, we used the GRADE method (32). Study constraints, indirectness of evidence, unexplained heterogeneity or discrepancy of results, imprecision of outcomes, and a high chance of publication bias are five conditions that determine the quality of the evidence (33). The summary of data tables was available on the GRADEpro or GRADEpro GDT website (www.gradepro.org) (34). The quality of the evidence and the RoB were evaluated independently by two reviewers (QZh and SZ). When in question, the decision was made after consulting another reviewer (SYL).

2.7. Statistical analysis

The statistics analysis was completed using Review Manager 5.4 software. In order to combine trials that measured the same result using several scales, the analysis of continuous outcomes was done by computing the SMD with 95% CI. If there were many experimental or sham stimulation groups included in the study, we pooled the experimental or control groups in an attempt to eliminate the number of comparisons (35). A fixed-effects model was employed for no or small heterogeneity studies (i.e., $P \ge 0.1$ or $I^2 \le 50\%$), whereas the random-effects model was used for high heterogeneity studies (i.e., P < 0.1 or $I^2 > 50\%$). The likelihood of publication bias was evaluated for a meta-analysis using a funnel plot analysis. In addition, we divided the data into subgroups based on age, location of the vibration, frequency, and duration. When the literature only provided the median or range of data, the mean and standard deviation were estimated

according to a validated mathematical formula proposed by Luo et al. (36).

3. Results

3.1. Literature selection

A total of 296 publications were identified (15 articles from PubMed, 55 articles from Web of Science, 34 articles from Embase, 30 articles from Medline, 17 articles from CENTRAL, 109 articles from CNKI, and 36 articles from Wang Fang); these were added to Endnote X9 (Clarivate Analytics). A total of 108 articles kept the removal of duplicates. A total of 24 publications were left after going over the titles and abstracts and eliminating reviews and other irrelevant studies. Finally, 13 of the 24 articles that were evaluated for eligibility were rejected: five because they were not RCTs; three because the aim of the comparison was to the combined efficacy of WBV plus additional treatments, not the effect of WBV alone; two because needed data was unavailable; one because it was an unpublished article; one because it had only one session and one because the outcome was not assessed by MAS. Thus, 11 articles (13, 23, 26, 37-44) were ultimately included in this meta-analysis. In Figure 1, the entire flowchart of the study screening process is displayed.

3.2. Characteristics of the included studies

Our research comprised a total of 11 studies covering 475 patients with post-stroke spasticity (252 participants in the experimental group, and 223 in the control group). In the experimental group, the intervention was WBV or conventional treatment supplemented with WBV, whereas the control group received sham vibration or conventional treatment. For spasticity sites, nine articles (13, 23, 26, 37, 38, 40–42, 44) included patients with lower limb spasticity and two articles (39, 43) included patients with upper limb spasticity. The fundamental features of the included research were outlined in Table 1. With regard to the outcome measure, all included articles reported the MAS. The characteristics of participants,

TABLE 2 Participant characteristics, vibration parameters, and interventions.

Included study	Participant characteristics	Vibration parameters	Interventions	Outcome	Measurement time points	Adverse events	Follow-u time
Liao et al. (41)	Gender(M/F): 62/22	Frequency: 20/30 Hz	VG1: HWBV + Dynamic exercise 15 min × 3/weeks × 30	MAS, Isokinetic testing	Within 1 week after 30 treatment sessions	One participant from the	/
	Mean age: 61.2	Amplitude: 1 mm	VG2: LWBV + Dynamic exercise 15 min × 3/weeks × 30			LWBV group reported mild knee pain after WBV therapy	
	Time since stroke: >6 months	Duration of the vibration: 15 min	CG: Dynamic exercise 15 min × 3/weeks × 30			and five reported fatigues	
			Position: stand position				
Lee et al. (39)	Gender (M/F): 24/21	Frequency: 5–15 Hz	VG1: WBV + TRT 60 min \times 3/weeks \times 4 w	MAS, FMA, Maximal grip strength	4 weeks	/	/
	Mean age: 59.3	Amplitude: 1–6 mm	VG2: WBV + TUE 60 min \times 3/weeks \times 4 w	strength			
	Time since stroke: >6 months	Duration of the vibration: 30 min	CG: TUE 60 min × 3/weeks × 4 w				
			Position: seated in front of the platform				
Pang et al. (13)	Gender (M/F): 58/24	Frequency: 20–30 Hz	VG: WBV + six different exercises 15 min × 3/weeks × 8 w	MAS, Isokinetic testing	8 weeks	Not reported	3 months
	Mean age: 57.35	Amplitude: 0.44–0.6 mm	CG: Sham vibration + six different exercises 15 min × 3/weeks × 8 w				
	Time since stroke: >6 months	Duration of the vibration: 15 min	Position: stand position				
Alp et al. (23)	Gender (M/F): 19/2	Frequency: 40 Hz	VG: WBV + exercise 20 min \times 3/weeks \times 4 w	MAS, FIM, 10 mWT	4 weeks	1	3, 6 months
	Mean age: 60.1	Amplitude: 4 mm	CG: Sham vibration + exercise 20 min × 3/weeks × 4 w				
	Time since stroke: >12 months	Duration of the vibration: 5 min	Position: stand position				
Brogårdh et al.	Gender (M/F): 25/6	Frequency: 25 Hz	VG: WBV 2/weeks \times 6 w	MAS, BBS,	6 weeks	Not reported	1
(26)	Mean age: 62.15	Amplitude: 3.75 mm	CG: Sham vibration 2 /weeks \times 6 w	Gait performance, stroke impact			
	Time since stroke: >6 months	Duration of the vibration:7 min	Position: stand position	scale			
Hwang (42)	Gender (M/F): 10/8	Frequency: 20–30 Hz	VG: WBV + CPT 30 min \times 5/weeks \times 4 w	MAS, BBS, MMT, FAC,	4 weeks	Not reported	
	Mean age: 68.1	Amplitude: 2–3 mm	CG: CPT 30 min × 5/weeks × 4 w	MBI			
	Time since stroke: <6 weeks	Duration of the vibration: 10 min	Position: stand position				
Wang et al. (43)	Gender (M/F): 27/6	Frequency: 4–6 Hz	VG: WBV + CPT 6/weeks \times 4 w	MAS, RMS, FMA, MBI	4 weeks	/	/
	Mean age: 48.8	Amplitude: 4 mm	CG: CPT 6/weeks \times 4 w				
	Time since stroke: ≤1 month	Duration of the vibration: 10 min	Position: sit on the vibration platform				
Li et al. (40)	Gender (M/F): 34/11	Frequency: 30 Hz	VG: WBV + CPT 6/weeks × 8 w	MAS, FMA, Gait analysis	8 weeks	Not reported	/
	Mean age: 48.3	Amplitude: 0.5 mm	CG: CPT 6/weeks \times 8 w				
	Time since stroke: ≤1 month	Duration of the vibration: 10 min	Position: stand position				

(Continued)

TABLE 2 (Continued)

Included study	Participant characteristics	Vibration parameters	Interventions	Outcome	Measurement time points	Adverse events	Follow-up time
Wei (44)	Gender (M/F): 28/13	Frequency: 18–25 Hz	VG: WBV + Bobath 55 min \times 5/weeks \times 4 w	MAS	4 weeks	/	/
	Mean age: 58.1	Amplitude: 9 mm	CG: Bobath 55 min \times 5/weeks \times 4 w				
		Duration of the vibration: 10 min	Position: stand position				
He (38)	Gender (M/F): 43/17	Frequency: 4 Hz	VG1: WBV + AT + CPT 5/weeks \times 4 w	MAS	4 weeks	Not reported	/
	Mean age: 58.1	Amplitude: 4 mm	VG2: WBV + CPT 5/weeks \times 4 w				
	Time since stroke: 2 weeks—6 months	Duration of the vibration: 15 min	CG: CPT 5/weeks \times 4 w				
			Position: stand position				
Xiao et al. (37)	Gender (M/F): 27/23	Frequency: 20–30 Hz	VG: WBV + ESWT + CPT 5/weeks × 4 w	MAS, BBS, FMA, Gait	4 weeks	1	/
	Mean age: 63.6	Amplitude: 2–3 mm	CG: ESWT + CPT 5/weeks × 4 w	analysis			
	Time since stroke: >3 months	Duration of the vibration: 15 min	Position: stand position				

VG, vibration group; CG, control group; TRT, task-related training; TUT, traditional upper training; CPT, conventional physical training; AT: acupuncture therapy; HWBV, high-intensity whole-body vibration; LWBV, low-intensity whole-body vibration; MAS, Modified Ashworth Scale; UDRS, Unified trunk assessment for dystonia; FMA, Fugl-Meyer exercise score; 10 mWT, 10-m walking test; FIM, Functional Independence Scale; RMS, root mean square value of surface EMG; MBI, modified Barthel index; PASS, score for posture control; ESWT, extracorporeal shock wave therapy; BBS, Berg Balance Scale; FAC: functional ambulation category scale.

vibration parameters, and intervention schemes are outlined in Table 2.

3.3. Risks of bias and level of evidence

We discovered moderate-quality evidence for the possible impact of WBV in alleviating spasticity based on the evaluation criteria. We discovered that the reliability of the evidence was negatively impacted by the possibility of uncertainty bias and a limited number of included participants. As shown in Figure 2, there was moderatequality evidence that WBV might have an impact on the decrease of spasticity. The evidence's quality was diminished by the uncertain danger of bias and the imprecision of the participants included in subgroups.

The evaluation of the potential for bias in the included studies is summarized in Supplementary Table S1. Overall, according to the Cochrane Bias Risk Scale, four studies (13, 26, 39, 43) met five lowbias risk criteria, three studies (23, 37, 41) met four criteria, two studies (38, 42) met three criteria, one study (40) met two criteria, and one study (44) only met one low-bias standard. We summarized the results as follows: (1) Random sequence generation: except Sung (42) using a randomization method of high bias risk, all of the other included studies described a method of random sequence generation; (2) Allocation hidden: four studies (13, 26, 39, 41) reported a clear random assignment scheme and the rest of studies did not report; (3) Implementation bias and measurement bias: eight studies and four studies, respectively, were found to have a low risk of implementation and measurement bias. The studies by Wei (44), Li et al. (40), and He (38) were unclear in these two respects: (4) Follow-up bias: only the studies by Wei (44) indicated missing data, which means the remaining were deemed to low risk; (5) Reporting bias and other bias: other possible sources of bias could not be found, and not all research used selective reporting (Figures 3, 4).

3.4. Meta-analysis

3.4.1. Overall meta-analysis

To explore the effectiveness of WBV in relieving spasticity, it was known from the forest plot analysis that when compared to the control group, WBV or WBV used in conjunction with other intervention modalities was linked to a reduction in muscular spasticity (SMD = -0.26, 95% CI: -0.44 to -0.07, P = 0.006) (Figure 5). An included research (37) comparing the effect of WBV combined with extracorporeal shock wave therapy on spasticity and sham stimulation combined with extracorporeal shock wave therapy. According to this study, when compared to other therapies, the use of WBV together with extracorporeal shock wave therapy significantly improves the curative outcomes.

3.4.2. Subgroup analysis based on the course of stroke

Regarding the course of a stroke, WBV did not significantly reduce spasticity in patients with chronic stroke (>6 months) vs. the control group (SMD = -0.16, 95% CI: -0.42 to 0.09, P = 0.21) (Figure 6); however, for those with acute and subacute stroke (0–6 months), it dramatically improved the outcomes (SMD = -0.39, 95% CI: -0.68 to -0.09, P = 0.01) (Figure 6).

	N₂ of	Certainty of	Relative	Anticipated a	bsolute effect
Outcomes	participants (studies) Follow-up	the evidence (GRADE)	effect (95% CI)	Risk with Sham	Risk difference with WBV
Post-stroke spasticity (PSS) assessed with: MAS Scale from: 0 to 4	475 (11 RCTs)	⊕⊕⊕⊖ Moderate	-	-	SMD 0.26 Si lower (0.44 lower t 0.07 lower)
Spasticity Sites (Upper limb)	63 (2 RCTs)	Hoderate ^a	-	-	SMD 0.53 S lower (1.04 lower 0.03 higher
Spasticity Sites (Lower limb)	412 (9 RCTs)	⊕⊕⊕⊖ Moderate ^b	-	-	SMD 0.21 S lower (0.4 lower t 0.01 lower
Frequency (<20Hz)	103 (3 RCTs)	⊕⊕⊕⊖ Moderate ^a	-	-	SMD 0.58 S lower (0.98 lower 0.19 lower
Frequency(20Hz-30Hz)	351 (7 RCTs)	⊕⊕⊖O Low ^{a,b}	-	-	SMD 0.21 S lower (0.42 lower 0.01 higher
Duration (5 min)	52 (2 RCTs)	⊕⊕⊖O Low ^{a,c}	-	-	SMD 0.18 S lower (0.73 lower 0.38 higher
Duration (10 min)	137 (4 RCTs)	⊕⊕⊖O Low ^{a,b}	-	-	SMD 0.41 S lower (0.75 lower 0.07 lower
Duration (15 min)	256 (4 RCTs)	⊕⊕⊖O Low ^{a,b}	-	-	SMD 0.2 SI lower (0.45 lower 0.06 higher
Age (<60)	271 (6 RCTs)	⊕⊕⊖O Low ^{a,b}	-	-	SMD 0.41 S lower (0.66 lower 0.17 lower
Age (≥60)	204 (5 RCTs)	⊕⊕⊕⊖ Moderate ^a	-	-	SMD 0.05 S lower (0.33 lower 0.24 higher
Acute and subacute stroke (0-6 months)	186 (5 RCTs)	⊕⊕⊖⊖ Low ^{a,b}	-	-	SMD 0.39 S lower (0.68 lower 0.09 lower
Chronic stroke (>6 months)	248 (5 RCTs)	⊕⊕⊕⊖ Moderate ^a	-	-	SMD 0.16 S lower (0.42 lower 0.09 higher

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; SMD: standardised mean difference

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

a. Less than 400 subjects.

b. The risk of bias in the study is ambiguous, which may reduce the credibility of the effect estimates.

c. Moderate heterogeneity (50%<l²<75%).

FIGURE 2


Quality of evidence for the included studies (GRADE).

3.4.3. Subgroup analysis based on the age

Regarding age, for patients younger than 60 years, spasticity was dramatically reduced in contrast to the control group when WBV was added to other therapies (SMD = -0.41, 95% CI: -0.66 to -0.17, P = 0.0008)(Figure 7), while those older than 60 did not have the same improvement (SMD = 0.05, 95% CI: -0.33 to 0.24, P = 0.75) (Figure 7).

3.4.4. Subgroup analysis based on spasticity sites

Regarding spasticity sites, for patients with upper limb spasticity, WBV was more effective than the control treatments when added to



other treatments (SMD = -0.53, 95% CI: -1.04 to 0.03, P = 0.03) (Figure 8); for patients with a lower limb (SMD = -0.21, 95% CI: -0.40 to -0.01, P = 0.04), WBV was added to other therapies, and it also outperformed the control treatments (Figure 8).

3.4.5. Subgroup analysis based on vibration frequency


Regarding the vibration frequency selected in the included study, it was also found that the signal distortion of the high-frequency vibration (>30 Hz) was more serious, while WBV frequencies below 20 Hz may result in resonance effects, amplifying the vibration signal and perhaps having negative effects (45). Therefore, we chose to bounded 20 and 30 Hz. Three studies revealed that vibration frequencies below 20 Hz were superior for reducing post-stroke spasticity (38, 39, 43) (SMD = -0.58, 95% CI: -0.98 to -0.19, P = 0.004) (Figure 9). However, for frequencies between 20 Hz and 30 Hz (SMD = -0.21, 95% CI: -0.42 to 0.01, P = 0.06), other therapies did not benefit from the inclusion of WBV over the control treatments (Figure 9).

3.4.6. Subgroup analysis based on vibration duration

Regarding vibration duration, four studies (40, 42–44) performed 10 min of vibration, and the effects of WBV were better than those applied 5 and 15 min of vibration to patients with spasticity (SMD = -0.41, 95% CI: -0.75 to -0.07, P = 0.02) (Figure 10).

3.5. Long-term effects and adverse effects

A follow-up evaluation of WBV for spasticity post-stroke was only reported in two randomized clinical trials (13, 23). Pang et al. (13) reported that knee spasticity levels had a decreasing trend and the MAS score was significantly lower than baseline at 1 month after WBV, the MAS score of the ankle joint, however, did not significantly change over time. Alp et al. (23) reported that ankle spasticity levels decreased gradually at the 3- and 6-month follow-ups. As for the adverse effects, in five studies, no notable serious adverse events associated with WBV were reported (13, 26, 38, 40, 42). According



		eriment			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
Alp et al. 2018	2.25	0.595	10	2	0.577	11	4.5%	0.41 [-0.46, 1.28]	
Brogårdh et al. 2012	1.83	1.98	16	3.72	4.02	15	6.5%	-0.59 [-1.31, 0.13]	
He Xi et al. 2017	0.9	1.07	20	1.6	1	20	8.3%	-0.66 [-1.30, -0.02]	
Lee et al. 2016	14.21	3.01	15	15.08	3.9	15	6.5%	-0.24 [-0.96, 0.48]	
Li Zhe et al. 2014	1.7	0.45	23	1.93	0.56	22	9.6%	-0.45 [-1.04, 0.15]	
Liao et al. 2016	1	1.52	56	1	1.56	28	16.4%	0.00 [-0.45, 0.45]	
Pang et al. 2013	0.427	0.489	41	0.6	0.72	41	17.8%	-0.28 [-0.71, 0.16]	
Sung et al. 2018	1	0.001	9	1	0.001	9	3.9%	0.00 [-0.92, 0.92]	
Wang Guosheng et al. 2018	1.41	0.54	17	1.88	0.58	16	6.6%	-0.82 [-1.53, -0.10]	
Wei Aifang et al. 2019	1.06	0.114	20	1.23	0.95	21	8.9%	-0.24 [-0.86, 0.37]	
Xiao Le et al. 2022	1.36	0.79	25	1.36	0.79	25	11.0%	0.00 [-0.55, 0.55]	-+-
Total (95% CI)			252			223	100.0%	-0.26 [-0.44, -0.07]	•
Heterogeneity: Chi ² = 9.76, df:	= 10 (P =	0.46);1	² = 0%						+ <u> </u>
Test for overall effect: Z = 2.76	(P = 0.0)	06)							-4 -2 U 2 · Favours [experimental] Favours [control]

FIGURE 5

Forest plot analysis of the efficacy of WBV on spasticity compared with control.

	Exp	erimenta	al	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
7.1.1 Acute and subacute stro	ke(0-6	months))						
He Xi et al. 2017	0.9	1.07	20	1.6	1	20	9.1%	-0.66 [-1.30, -0.02]	
⊥i Zhe et al. 2014	1.7	0.45	23	1.93	0.56	22	10.5%	-0.45 [-1.04, 0.15]	
Sung et al. 2018	1	0.001	9	1	0.001	9	4.3%	0.00 [-0.92, 0.92]	
Vang Guosheng et al. 2018	1.41	0.54	17	1.88	0.58	16	7.3%	-0.82 [-1.53, -0.10]	
(iao Le et al. 2022	1.36	0.79	25	1.36	0.79	25	12.0%	0.00 [-0.55, 0.55]	
Subtotal (95% Cl)			94			92	43.3%	-0.39 [-0.68, -0.09]	•
Heterogeneity: Chi ² = 4.71, df =	: 4 (P = I	0.32); I 2 =	= 15%						
Fest for overall effect: Z = 2.58	(P = 0.0	10)							
7.1.2 Chronic stroke(>6 mont	1s)								
Np et al. 2018	2.25	0.595	10	2	0.577	11	4.9%	0.41 [-0.46, 1.28]	
Brogårdh et al. 2012	1.83	1.98	16	3.72	4.02	15	7.1%	-0.59 [-1.31, 0.13]	
_ee et al. 2016	14.21	3.01	15	15.08	3.9	15	7.2%	-0.24 [-0.96, 0.48]	
Liao et al. 2016	1.5	0.45	56	1.5	0.45	28	18.0%	0.00 [-0.45, 0.45]	-+-
Pang et al. 2013	0.427	0.489	41	0.6	0.72	41	19.6%	-0.28 [-0.71, 0.16]	
Subtotal (95% Cl)			138			110	56.7%	-0.16 [-0.42, 0.09]	•
Heterogeneity: Chi² = 3.82, df =		~ .	= 0%						
Fest for overall effect: Z = 1.26	(P = 0.2	1)							
fotal (95% CI)			232			202	100.0%	-0.26 [-0.45, -0.07]	◆
Heterogeneity: Chi² = 9.76, df =	9 (P = I	0.37); I ž =	= 8%						-4 -2 0 2
Fest for overall effect: Z = 2.65	(P = 0.0	08)							-4 -2 0 2 Favours [experimental] Favours [control]
Fest for subaroup differences:	Chi ^z = 1	.24. df=	1 (P =	0.27). ř	² = 19.2	%			ravours (experimental) ravours (control)
URE 6									
rest plot analysis of the effic	any of	W/R\/ in	cuba		lividod	on the		of a stroko	

to one study (41), five modest side effects (fatigue, redness of the skin, mild headache, and drowsiness) and 1 out of 84 patients experienced mild knee pain following the WBV.

3.6. Publication bias

For each observation index, funnel plots were produced (Supplementary Figure S2). The funnel plots show that the included studies were generally symmetric and focused, indicating that there was little to no indication of publication bias.

4. Discussion

This meta-analysis was intended to assess the effectiveness and safety of WBV in treating individuals with post-stroke spasticity, and simultaneously, an appropriate application scheme was also explored by analyzing some possible influencing parameters or factors. Overall, the analysis comprised a total of 11 trials with 475 individuals. We identified moderate-quality proof that WBV was regarded as a safe and effective adjunctive therapy in patients with post-stroke spasticity, especially when used at a vibration frequency below 20 Hz for 10 min, for patients with a stroke under the age of 60 years who have post-stroke spasticity in their upper and lower limbs.

As mentioned in a prior review (24), it came to the conclusion that there was weak proof that short-term WBV therapy lowers lower limb spasticity in patients suffering neurological disorders, which was consistent with our conclusion. Lucrezia et al. (46) also found in contrast to chronic patients, those who were acute or subacute appear to benefit from vibration therapy more. However, the appropriate WBV treatment parameters for individuals with poststroke spasticity have not been identified by prior investigations. Compared with early reviews (24, 46), this review conducted a more comprehensive subgroup analysis of the factors that may affect treatment efficacy, including age, stroke course, and vibration parameters (frequency, time, and location). Given the available research data, our study offered safe and effective WBV settings to relieve post-stroke spasticity despite the lack of high-quality evidence. However, a different systematic review (47) found inadequate data to

	Exp	eriment	al	C	ontrol		S	td. Mean Difference	Std. Mean Difference
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
1.1 Age(<60)									
e Xi et al. 2017	0.9	1.07	20	1.6	1	20	8.3%	-0.66 [-1.30, -0.02]	
ee et al. 2016	14.21	3.01	15	15.08	3.9	15	6.5%	-0.24 [-0.96, 0.48]	
i Zhe et al. 2014	1.7	0.45	23	1.93	0.56	22	9.6%	-0.45 [-1.04, 0.15]	
ang et al. 2013	0.427	0.489	41	0.6	0.72	41	17.8%	-0.28 [-0.71, 0.16]	
/ang Guosheng et al. 2018	1.41	0.54	17	1.88	0.58	16	6.6%	-0.82 [-1.53, -0.10]	
/ei Aifang et al. 2019	1.06	0.114	20	1.23	0.95	21	8.9%	-0.24 [-0.86, 0.37]	
ubtotal (95% Cl)			136			135	57.7%	-0.41 [-0.66, -0.17]	•
eterogeneity: Chi² = 2.72, df= est for overall effect: Z = 3.36			- 070						
1.2 Age(≥60)									
lp et al. 2018	2.25	0.595	10	2	0.577	11	4.5%	0.41 [-0.46, 1.28]	
rogårdh et al. 2012	1.83	1.98	16	3.72	4.02	15	6.5%	-0.59 [-1.31, 0.13]	
iao et al. 2016	1.5	0.45	56	1.5	0.45	28	16.4%	0.00 [-0.45, 0.45]	
ung et al. 2018	1	0.001	9	1	0.001	9	3.9%	0.00 [-0.92, 0.92]	
iao Le et al. 2022	1.36	0.79	25	1.36	0.79	25	11.0%	0.00 [-0.55, 0.55]	
ubtotal (95% CI)			116			88	42.3%	-0.05 [-0.33, 0.24]	•
eterogeneity: Chi² = 3.30, df= est for overall effect: Z = 0.32		~ ~ ~	= 0%						
otal (95% CI)			252			223	100.0%	-0.26 [-0.44, -0.07]	•
eterogeneity: Chi² = 9.76, df = est for overall effect: Z = 2.76 est for subαroup differences:	(P = 0.0	06)		0.05), ľ	² = 73.3			,,	-4 -2 0 2 4 Favours [experimental] Favours [control]

	Exp	eriment	al	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
3.1.1 Upper limb									
.ee et al. 2016	14.21	3.01	15	15.08	3.9	15	6.5%	-0.24 [-0.96, 0.48]	
Vang Guosheng et al. 2018	1.41	0.54	17	1.88	0.58	16	6.6%	-0.82 [-1.53, -0.10]	
Subtotal (95% Cl)			32			31	13.2%	-0.53 [-1.04, -0.03]	•
Heterogeneity: Chi ² = 1.24, df	= 1 (P = 0	0.27); I [≥]	= 19%						
est for overall effect: Z = 2.06	(P = 0.0-	4)							
.1.2 Lower limb									
Np et al. 2018	2.25	0.595	10	1.75	0.878	11	4.3%	0.63 [-0.25, 1.52]	+
Brogårdh et al. 2012	1.83	1.98	16	3.72	4.02	15	6.5%	-0.59 [-1.31, 0.13]	
He Xi et al. 2017	0.9	1.07	20	1.6	1	20	8.3%	-0.66 [-1.30, -0.02]	
Li Zhe et al. 2014	1.7	0.45	23	1.93	0.56	22	9.6%	-0.45 [-1.04, 0.15]	
_iao et al. 2016	1.5	0.45	56	1.5	0.45	28	16.4%	0.00 [-0.45, 0.45]	
Pang et al. 2013	0.427	0.489	41	0.6	0.72	41	17.8%	-0.28 [-0.71, 0.16]	
Bung et al. 2018	1	0.001	9	1	0.001	9	4.0%	0.00 [-0.92, 0.92]	
/Vei Aifang et al. 2019	1.06	0.114	20	1.23	0.95	21	8.9%	-0.24 [-0.86, 0.37]	
(iao Le et al. 2022	1.36	0.79	25	1.36	0.79	25	11.0%	0.00 [-0.55, 0.55]	
Subtotal (95% CI)			220			192	86.8%	-0.21 [-0.40, -0.01]	◆
leterogeneity: Chi ² = 8.78, df	= 8 (P = 0	0.36); I ₹	= 9%						
est for overall effect: Z = 2.06	(P = 0.0	4)							
otal (95% CI)			252			223	100.0%	-0.25 [-0.43, -0.07]	◆
Heterogeneity: Chi² = 11.40, df = 10 (P = 0.33); l² = 12%								+	
Fest for overall effect: Z = 2.67	(P = 0.0)	08)						-	Favours [experimental] Favours [control]
Test for subaroup differences	Chi ^z = 1	.38. df=	: 1 (P =	0.24). I	²= 27.5	%			ravours (experimental) Favours (control)
URE 8 rest plot analysis of the effi									

either support or disprove the claim that WBV can relieve spasticity in patients with stroke. The short number of studies included the low number of studies that produced statistically significant outcomes, and the wide range of intervention strategies may be responsible for this conclusion. As the studies evaluating how WBV affects muscular spasticity post-stroke have significantly increased, we believe that the conclusions of this study need to be further updated with increasing evidence on the effectiveness of WBV for spasticity today.

As far as we are aware, this is the first meta-analysis to thoroughly compile and evaluate the effectiveness and safety of WBV

in the treatment of post-stroke spasticity; besides, some influencing parameters and factors were also explored, offering support for the clinical application of WBV. Furthermore, from the results of the subgroup analysis, we filled the current gap in the clinical use of WBV in post-stroke spasticity treatment by offering a reliable and secure prescription for it. The Cochrane Collaboration's guidelines and criteria were strictly adhered to in this meta-analysis (31). In addition, as determined by the strict inclusion and exclusion standards, the most relevant randomized clinical studies were included. To prevent conclusions from being biased or misleading, we evaluated the quality

	Exp	eriment	al	C	Control		S	td. Mean Difference	Std. Mean Difference
itudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
.1.1 Frequency (f<20Hz)									
le Xi et al. 2017	0.9	1.07	20	1.6	1	20	8.7%	-0.66 [-1.30, -0.02]	
ee et al. 2016	14.21	3.01	15	15.08	3.9	15	6.8%	-0.24 [-0.96, 0.48]	
Vang Guosheng et al. 2018	1.41	0.54	17	1.88	0.58	16	6.9%	-0.82 [-1.53, -0.10]	
Subtotal (95% CI)			52			51	22.4%	-0.58 [-0.98, -0.19]	•
leterogeneity: Chi ^z = 1.34, df	= 2 (P = 0	0.51); I ^z	= 0%						
est for overall effect: Z = 2.88	(P = 0.0)	D4)							
.1.2 Frequency (20Hz≤f≤3	0Hz)								
Brogårdh et al. 2012	1.83	1.98	16	3.72	4.02	15	6.8%	-0.59 [-1.31, 0.13]	
i Zhe et al. 2014	1.7	0.45	23	1.93	0.56	22	10.1%	-0.45 [-1.04, 0.15]	
iao et al. 2016	1.5	0.45	56	1.5	0.45	28	17.2%	0.00 [-0.45, 0.45]	
Pang et al. 2013	0.427	0.489	41	0.6	0.72	41	18.6%	-0.28 [-0.71, 0.16]	
Bung et al. 2018	1	0.001	9	1	0.001	9	4.1%	0.00 [-0.92, 0.92]	
Vei Aifang et al. 2019	1.06	0.114	20	1.23	0.95	21	9.3%	-0.24 [-0.86, 0.37]	
íiao Le et al. 2022	1.36	0.79	25	1.36	0.79	25	11.5%	0.00 [-0.55, 0.55]	
ubtotal (95% CI)			190			161	77.6%	-0.21 [-0.42, 0.01]	•
leterogeneity: Chi ² = 3.34, df	= 6 (P = 0	0.77); I₹	= 0%						
est for overall effect: Z = 1.89	(P = 0.0)	6)							
otal (95% CI)			242			212	100.0%	-0.29 [-0.48, -0.10]	•
leterogeneity: Chi ² = 7.37, df			= 0%						-4 -2 0 2 4
'est for overall effect: Ζ = 3.02 'est for subαroup differences			:1 (P =	0.100 J	≅= 62 9	%			Favours [experimental] Favours [control]
corror caparous amoreneos				0.107.1	52.5	~			

	Expe	eriment	al	0	Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
5.1.1 Duration(5 min)									
Alp et al. 2018	2.25	0.595	10	2	0.577	11	4.8%	0.41 [-0.46, 1.28]	
Brogårdh et al. 2012	1.83	1.98	16	3.72	4.02	15	6.9%	-0.59 [-1.31, 0.13]	
Subtotal (95% CI)			26			26	11.7%	-0.18 [-0.73, 0.38]	
Heterogeneity: Chi ² = 3.00, df	= 1 (P = 0).08); I ^z	= 67%						
Fest for overall effect: Z = 0.63	(P = 0.53	3)							
5.1.2 Duration(10 min)									
_i Zhe et al. 2014	1.7	0.45	23	1.93	0.56	22	10.3%	-0.45 [-1.04, 0.15]	
Sung et al. 2018	1	0.001	9	1	0.001	9	4.2%	0.00 [-0.92, 0.92]	
Vang Guosheng et al. 2018	1.41	0.54	17	1.88	0.58	16	7.1%	-0.82 [-1.53, -0.10]	
Vei Aifang et al. 2019	1.06	0.114	20	1.23	0.95	21	9.5%	-0.24 [-0.86, 0.37]	_ _
Subtotal (95% CI)			69			68	31.1%	0.41[-0.75, -0.07]	•
Heterogeneity: Chi² = 2.31, df Fest for overall effect: Z = 2.35									
5.1.3 Duration(15min)									
He Xi et al. 2017	0.9	1.07	20	1.6	1	20	8.9%	-0.66 [-1.30, -0.02]	
liao et al. 2016.	1.5	0.45	56	1.5	0.45	28	17.5%	0.00 [-0.45, 0.45]	
Pang et al. 2013	0.427		41	0.6	0.72	41	19.1%	-0.28 [-0.71, 0.16]	
Gao Le et al. 2022	1.36	0.79	25	1.36	0.79	25	11.7%	0.00 [-0.55, 0.55]	
Subtotal (95% CI)			142			114	57.2%	-0.20 [-0.45, 0.06]	•
Heterogeneity: Chi ^z = 3.39, df Fest for overall effect: Z = 1.52		~ ~ ~	= 11%						
fotal (95% CI)			237			208	100.0%	-0.26 [-0.45, -0.07]	◆
Heterogeneity: Chi ² = 9.76, df	= 9 (P = 0	0.37); I [≠]	= 8%						<u> </u>
Fest for overall effect: Z = 2.68	(P = 0.0)	J7)						-	
Fest for subaroup differences	: Chi² = 1	.06. df=	= 2 (P =	0.59). I	²=0%				Favours [experimental] Favours [control]
URE 10									

of the evidence using GRADEpro GDT (48). Subgroup analysis of the moderate quality of evidence revealed WBV can reduce spasticity in the upper and lower limb after stroke, which was consistent with the conclusion of previous systematic reviews (49, 50). However, current studies have focused on the upper and lower limbs, and there are few studies on WBV for trunk muscle spasticity, and the effectiveness of trunk spasms is difficult to conclude at present. Therefore, to better comprehend how WBV affects post-stroke spasticity in other

clinically relevant body parts, especially the trunk, additional well-designed randomized clinical trials are required.

This review found low-quality evidence that patients with both acute and subacute stroke can benefit from WBV for post-stroke spasticity. Considering that spasticity gradually increased within 1 month of onset, while stroke survivors often present with limb weakness within 3 months (5), in survivors with acute and subacute stroke, the spasticity reduction would have been more considerable.

According to certain studies (50, 51), patients with an acute stroke who receive low vibration frequency (20 Hz) had stronger muscles than those in the control group. However, this conclusion required validation with more and higher quality RCTs due to the low quality of the literature evidence. Due to the low quality of the literature data, this finding needed to be validated with more randomized controlled trials of higher quality. Moreover, varying degrees of impairment may have different effects on soft tissue's properties, such as how much muscle atrophy, how much muscle turns into connective tissue, and how much sarcomere was lost (3), thus limiting the application of WBV.

The present study found moderate-quality evidence that WBV could effectively improve post-stroke spasticity at frequencies below 20 Hz. Some studies (41, 52) suggested that an enhanced vibration signal and possible negative effects can emerge from vibrations at frequencies below 20 Hz because of a significant resonance effect, such as internal organ damage. However, three of the included studies (37, 39, 44) used vibrations below 20 Hz, among which only a few produced mild adverse effects, and spasticity alleviation outperformed that of the control group by a large margin. Considering the outcomes of this study, WBV at frequencies <20 Hz can be applied to ameliorate post-stroke spasticity. We did not decide to carry out a subgroup analysis for the study with a frequency higher than 30 Hz because of the small number of inclusions. Since their greater peak acceleration values, high-frequency vibrations (>30 Hz) have the potential to cause damage (45), which may not be appropriate for patients with chronic stroke, many of whom have frail bones (53). Furthermore, the only included study (41) reported that some patients showed fatigue and discomfort at high frequency vibration. Some studies (54, 55) have shown that spasticity can be effectively treated by inducing frequencies between 20 and 30 Hz. Therefore, to strengthen the evidence for therapeutic application, more study is needed to confirm the impact and mechanism of different vibration frequencies on post-stroke spasticity.

Regarding the WBV duration, post-stroke spasticity can be effectively alleviated for the last 10 min. Four included trials (40, 42–44) that adopted a 10-min vibration time reported significant effects on spasticity improvement, and no withdrawal from the trial due to adverse effects. Hence, the present review suggests that 10 min of WBV as an adjunctive therapy was safe and effective for improving post-stroke spasticity.

Another important parameter is the posture of the patient. Due to the limited number of inclusions, only a systematic evaluation of patient posture was performed. Patient postures in 10 studies were standing posture, nine of which measured lower limb spasticity, and one measured trunk spasticity. In the other two studies, patients were in a seated posture, which studied upper limb spasticity. In research involving WBV training in a standing position, the majority of patients were asked to perform static or dynamic semi-squat training instead of a static upright standing station. Studies have found that static upright stations were prone to transmitting vibration to the head, which can lead to adverse reactions such as dizziness (56). There is plenty of evidence that knee flexion angles may impact the transmission of vibration to the head, which should be avoided. Abercromby et al. (57) demonstrated that when the knee flexion angle rises from 10 to 30, it appears that head transmissibility decreases, using a fixed setup (30 Hz and 4 mm). It can also be utilized with dynamic motions for WBV. The response to dynamic exercise was equivalent to static postures, according to a recent study (58) that looked at transmissibility to the head (frequencies between 20 and 50 Hz) during dynamic squats. Therefore, a certain knee flexion Angle can reduce the transmission of vibration to the head to reduce adverse reactions. Moreover, Boo et al. (59) found that chronic stroke patients with whole-body vibration training in a seated position had increased muscle tone and upper limb function. This may be related to an improvement in the postural control ability. Improving postural control can make arm movement more flexible and improve activities of daily living (60). Verheyden et al. (61) reported that sitting training was effective in improving postural control. Hence, to enhance upper limb function, it was advised to carry out rehabilitation activities while seated on shaky or moving surfaces, such as the vibration platform.

There are certain restrictions on the current meta-analysis. First, all the participants of this study were patients with mild to moderate spastic stroke. There has not been enough research done on the effectiveness of WBV in patients suffering from severe spasticity, thus, this conclusion may not be applied and extended to all patients with post-stroke spasticity. Second, the potential long-term effects of WBV cannot be determined because only two studies had a 3–6-month followed-up. Third, due to a variety of mixed factors, the results can be biased to some extent. These limitations, to some extent, limit the applicability of WBV and the credibility of the conclusions, and the conclusions drawn should be treated with caution. To assess how different vibrational parameters affect post-stroke spasticity, create optional treatment protocols, and provide scientific justification for the purpose of WBV therapeutic usage in the management of poststroke spasticity, additional prospective studies are required.

5. Conclusion

Based on current moderate evidence, it seems when used as an adjuvant therapy for 10 min at a frequency of <20 Hz, whole-body vibration has been proven to work best for upper and lower limb spasticity in patients with acute and subacute strokes under the age of 60 years. Studies of better quality are required in the future to examine its long-term safety and effectiveness, as well as the mechanism of action.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

QZe, JZ, and XZ: conception and design and typographical logic of the article. YZ, LC, and GL: literature selection and acquisition of data. QZh, SZ, and ShuL: analysis and interpretation of data and editing the article. ShiL, LH, and SC: study supervision and revising the article. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by the National Natural Science Foundation of China (Grant Nos. 82002380 and 82205245), the

Teaching Reform Project of Guangdong Province (JG2021013), the Teaching Reform Project of Southern Medical University (B120562249 and B121562247), Guangdong Provincial Health Suitable Technology Promotion Project (202206252011533513), Scientific Research Enlightenment Program of Southern Medical University (B522ZJ0103), College Student's Innovative Entrepreneurial Training Plan Program at the School Level of Southern Medical University (202212121336), and Guangdong Provincial College Students Innovation Training Program of 2022 (S202212121168).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sexspecific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* (2018) 392:1736–88. doi: 10.1016/S0140-6736(18)32203-7

2. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* (2021) 20:795–820. doi: 10.1016/S1474-4422(21)00252-0

3. Huang J, Qu Y, Liu L, Zhao K, Zhao Z. Efficacy and safety of transcranial direct current stimulation for post-stroke spasticity: a meta-analysis of randomised controlled trials. *Clin Rehabil.* (2022) 36:158–71. doi: 10.1177/026921552110 38097

4. Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. *Stroke.* (2010) 41:319–24. doi: 10.1161/STROKEAHA.109. 558619

5. Bethoux F. Spasticity management after stroke. *Phys Med Rehabil Clin N Am.* (2015) 26:625–39. doi: 10.1016/j.pmr.2015.07.003

6. Gu X, Zeng M, Cui Y, Fu J, Li Y, Yao Y, et al. Aquatic strength training improves postural stability and walking function in stroke patients. *Physiother Theory Pract.* (2022) 14:1–10. doi: 10.1080/09593985.2022.2049939

7. Lee SY, Im SH, Kim BR, Han EY. The Effects of a motorized aquatic treadmill exercise program on muscle strength, cardiorespiratory fitness, and clinical function in subacute stroke patients: a randomized controlled pilot trial. *Am J Phys Med Rehabil.* (2018) 97:533–40. doi: 10.1097/PHM.0000000000020

8. Abdullahi A, Wong TWL, Ng SSM. Rehabilitation of severe impairment in motor function after stroke: suggestions for harnessing the potentials of mirror neurons and the mentalizing systems to stimulate recovery. *Brain Sci.* (2022) 12:1311. doi: 10.3390/brainsci12101311

9. Oliveira MCB, Silva DRC, Cortez BV, Coêlho CKS, Silva FMS, Oliveira GBVP, et al. Mirror and vibration therapies effects on the upper limbs of hemiparetic patients after stroke: a pilot study. *Rehabil Res Pract.* (2018) 2018:1–6. doi: 10.1155/2018/61 83654

10. Sahin N, Ugurlu H, Karahan AY. Efficacy of therapeutic ultrasound in the treatment of spasticity: a randomized controlled study. *NRE.* (2011) 29:61–6. doi: 10.3233/NRE-2011-0678

11. Stein C, Fritsch CG, Robinson C, Sbruzzi G, Plentz RDM. Effects of electrical stimulation in spastic muscles after stroke: systematic review and meta-analysis of randomized controlled trials. *Stroke.* (2015) 46:2197–205. doi: 10.1161/STROKEAHA.115.009633

12. Cabanas-Valdés R, Calvo-Sanz J, Urrùtia G, Serra-Llobet P, Pérez-Bellmunt A, Germán-Romero A. The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. *Top Stroke Rehabil.* (2020) 27:137–57. doi: 10.1080/10749357.2019. 1654242

13. Pang MYC, Lau RWK, Yip SP. The effects of whole-body vibration therapy on bone turnover, muscle strength, motor function, and spasticity in chronic stroke: a randomized controlled trial. *Eur J Phys Rehabil Med.* (2013) 49:439–50.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023. 1074922/full#supplementary-material

14. Chan KS, Liu CW, Chen TW, Weng MC, Huang MH, Chen CH. Effects of a single session of whole body vibration on ankle plantarflexion spasticity and gait performance in patients with chronic stroke: a randomized controlled trial. *Clin Rehabil.* (2012) 26:1087–95. doi: 10.1177/0269215512446314

15. Rittweger J. Vibration as an exercise modality: how it may work, and what its potential might be. *Eur J Appl Physiol.* (2010) 108:877-904. doi: 10.1007/s00421-009-1303-3

16. Nielsen J, Petersen N, Crone C. Changes in transmission across synapses of Ia afferents in spastic patients. *Brain*. (1995) 118:995–1004. doi: 10.1093/brain/118.4.995

17. Hagbarth KE, Wallin G, Löfstedt L. Muscle spindle responses to stretch in normal and spastic subjects. *Scand J Rehabil Med.* (1973) 5:156–9.

18. Marconi B, Filippi GM, Koch G, Giacobbe V, Pecchioli C, Versace V, et al. Long-term effects on cortical excitability and motor recovery induced by repeated muscle vibration in chronic stroke patients. *Neurorehabil Neural Repair*. (2011) 25:48–60. doi: 10.1177/1545968310376757

19. Mileva KN, Bowtell JL, Kossev AR. Effects of low-frequency whole-body vibration on motor-evoked potentials in healthy men: corticospinal excitability during whole-body vibration exercise. *Exp Physiol.* (2009) 94:103–16. doi: 10.1113/expphysiol.2008.042689

20. Marconi B, Filippi GM, Koch G, Pecchioli C, Salerno S, Don R, et al. Long-term effects on motor cortical excitability induced by repeated muscle vibration during contraction in healthy subjects. *J Neurol Sci.* (2008) 275:51–9. doi:10.1016/j.ins.2008.07.025

21. Miyara K, Matsumoto S, Uema T, Noma T, Ikeda K, Ohwatashi A, et al. Effect of whole body vibration on spasticity in hemiplegic legs of patients with stroke. *Top Stroke Rehabil.* (2018) 25:90–5. doi: 10.1080/10749357.2017.1389055

22. Miyara K, Kawamura K, Matsumoto S, Ohwatashi A, Itashiki Y, Uema T, et al. Acute changes in cortical activation during active ankle movement after whole-body vibration for spasticity in hemiplegic legs of stroke patients: a functional near-infrared spectroscopy study. *Top Stroke Rehabil.* (2020) 27:67–74. doi: 10.1080/10749357.2019.1659639

23. Alp A, Efe B, Adali M, Bilgiç A, Demir Türe S, Coşkun S, et al. The impact of whole body vibration therapy on spasticity and disability of the patients with poststroke hemiplegia. *Rehabil Res Pract.* (2018) 2018:8637573. doi: 10.1155/2018/8637573

24. Alashram AR, Padua E, Annino G. Effects of whole-body vibration on motor impairments in patients with neurological disorders: a systematic review. *Am J Phys Med Rehabil.* (2019) 98:1084–98. doi: 10.1097/PHM.000000000001252

25. Sade I, Çekmece Ç, Inanir M, SelÇuk B, Dursun N, Dursun E. The effect of whole body vibration treatment on balance and gait in patients with stroke. *Noro Psikiyatr Ars.* (2020) 57:308–11. doi: 10.29399/npa.23380

26. Brogårdh C, Flansbjer UB, Lexell J. No specific effect of whole-body vibration training in chronic stroke: a double-blind randomized controlled study. *Arch Phys Med Rehabil.* (2012) 93:253–8. doi: 10.1016/j.apmr.2011.09.005

27. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* (2015) 4:1. doi: 10.1186/2046-4053-4-1

28. Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. *Emerg Med J.* (2020) 37:387. doi: 10.1136/emermed-2020-209567

29. Rauch F, Sievanen H, Boonen S, Cardinale M, Degens H, Felsenberg D, et al. Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. *J Musculoskelet Neuronal Interact.* (2010) 10:193–8.

30. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* (2011) 343:d5928. doi: 10.1136/bmj.d5928

31. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. *Cochrane Database Syst Rev.* (2019) 10:ED000142. doi: 10.1002/14651858.ED000142

32. Mendoza C, Kraemer P, Herrera P, Burdiles P, Sepúlveda D, Núñez E, et al. Clinical guidelines using the GRADE system (grading of recommendations assessment, development and evaluation). *Rev Med Chil.* (2017) 145:1463–70. doi: 10.4067/s0034-98872017001101463

33. Austin TM, Richter RR, Sebelski CA. Introduction to the GRADE approach for guideline development: considerations for physical therapist practice. *Phys Ther.* (2014) 94:1652–9. doi: 10.2522/ptj.20130627

34. Hu G, Zhang H, Wang Y, Cong D. Non-pharmacological intervention for rehabilitation of post-stroke spasticity: a protocol for systematic review and network meta-analysis. *Medicine*. (2021) 100:e25788. doi: 10.1097/MD.00000000025788

35. Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation for improving spasticity after stroke: a systematic review with meta-analysis. *J Rehabil Med.* (2016) 48:565–70. doi: 10.2340/16501977-2097

36. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res.* (2018) 27:1785–805. doi: 10.1177/0962280216669183

37. Xiao L, Liu C, Li Y, Deng Y, Xie B, Lin F, et al. Effects of whole body vibration combined with extracorporeal shock wave therapy on spasticity and balance gait parameters in hemiplegic patients with stroke. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* (2022) 47:755–61. doi: 10.11817/j.issn.1672-7347.2022.220063

38. He X. Clinical Observation of Acupuncture Combined with Whole Body Vertical Vibration in the Treatment of Calf Triceps Spasm After Stroke. Yuelu: Hunan University of Chinese Medicine (2020).

39. Lee JS, Kim CY, Kim HD. Short-term effects of whole-body vibration combined with task-related training on upper extremity function, spasticity, and grip strength in subjects with post-stroke hemiplegia: a pilot randomized controlled trial. *Am J Phys Med Rehabil.* (2016) 95:608–17. doi: 10.1097/PHM.00000000000454

40. Li Z, Wang G, Guo G. Observation on the effect of whole body vibration therapy on ankle flexion spasticity after stroke. *Chin J Rehabil Med.* (2014) 29:451–4.

41. Liao LR, Ng GYF, Jones AYM, Huang MZ, Pang MYC. Whole-body vibration intensities in chronic stroke: a randomized controlled trial. *Med Sci Sports Exerc.* (2016) 48:1227–38. doi: 10.1249/MSS.000000000000909

42. Hwang SI. Effects of whole-body vibration on the improvement of balance, gait and activities of daily living in patients with subacute stroke. *Soonchunhyang Med Sci.* (2018) 24:131–41. doi: 10.15746/sms.18.027

43. Wang G. sheng, Guo G, Li Z, Liang Y. Effect of whole body vibration therapy based on Bobath concept on upper limb spasm in stroke patients with hemiplegia. *Clin Med Eng.* (2018) 25:733–5.

44. Wei A. Effect of whole body vibration training combined with Bobath technique on lower limb motor function of patients with hemiplegia in spastic period. *Health Essential Read.* (2019) 33:56–8.

45. Kiiski J, Heinonen A, Järvinen TL, Kannus P, Sievänen H. Transmission of vertical whole body vibration to the human body. *J Bone Miner Res.* (2008) 23:1318–25. doi: 10.1359/jbmr.080315

46. Moggio L, de Sire A, Marotta N, Demeco A, Ammendolia A. Vibration therapy role in neurological diseases rehabilitation: an umbrella review of systematic reviews. *Disabil Rehabil.* (2022) 44:5741–9. doi: 10.1080/09638288.2021.1946175

47. Huang M, Liao LR, Pang MY. Effects of whole body vibration on muscle spasticity for people with central nervous system disorders: a systematic review. *Clin Rehabil.* (2017) 31:23–33. doi: 10.1177/0269215515621117

48. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. (2008) 336:924–6. doi: 10.1136/bmj.39489.470347.AD

49. Yang X, Xue X, Tu H, Li N. Effect of whole-body vibration training on the recovery of lower limb function in people with stroke: a systematic review and meta-analysis. *Disabil Rehabil.* (2022) 11:1–10. doi: 10.1080/09638288.2022.2138993

50. Park YJ, Park SW, Lee HS. Comparison of the effectiveness of whole body vibration in stroke patients: a meta-analysis. *BioMed Res Int.* (2018) 2018:1-10. doi: 10.1155/2018/5083634

51. Tihanyi J, Di Giminiani R, Tihanyi T, Gyulai G, Trzaskoma L, Horváth M. Low resonance frequency vibration affects strength of paretic and non-paretic leg differently in patients with stroke. *Acta Physiol Hung.* (2010) 97:172–82. doi: 10.1556/APhysiol.97.2010.2.3

52. Harazin B, Grzesik J. The transmission of vertical whole-body vibration to the body segments of standing subjects. J Sound Vib. (1998) 215:775–87.

53. Eng JJ, Pang MYC, Ashe MC. Balance, falls, and bone health: role of exercise in reducing fracture risk after stroke. *J Rehabil Res Dev.* (2008) 45:297–313. doi: 10.1682/JRRD.2007.01.0014

54. van Nes IJW, Latour H, Schils F, Meijer R, van Kuijk A, Geurts ACH. Long-term effects of 6-week whole-body vibration on balance recovery and activities of daily living in the post-acute phase of stroke: a randomized, controlled trial. *Stroke.* (2006) 37:2331–5. doi: 10.1161/01.STR.0000236494.62957.f3

55. Furness TP, Maschette WE. Influence of whole body vibration platform frequency on neuromuscular performance of community-dwelling older adults. *J Strength Cond Res.* (2009) 23:1508–13. doi: 10.1519/JSC.0b013e3181a4e8f9

56. Liu Y, Fan Y, Chen X. Effects of whole-body vibration training with different body positions and amplitudes on lower limb muscle activity in middle-aged and older women. *Dose Resp.* (2022) 20:155932582211129. doi: 10.1177/15593258221112960

57. Abercromby AFJ, Amonette WE, Layne CS, Mcfarlin BK, Hinman MR, Paloski WH. Variation in neuromuscular responses during acute whole-body vibration exercise. *Med Sci Sports Exer.* (2007) 39:1642–50. doi: 10.1249/mss.0b013e318093f551

58. Caryn RC, Dickey JP. Transmission of acceleration from a synchronous vibration exercise platform to the head during dynamic squats. *Dose Resp.* (2019) 17:155932581982746. doi: 10.1177/1559325819827467

59. Boo JA, Moon SH, Lee SM, Choi JH, Park SE. Effect of whole-body vibration exercise in a sitting position prior to therapy on muscle tone and upper extremity function in stroke patients. *J Phys Ther Sci.* (2016) 28:558–62. doi: 10.1589/jpts.28.558

60. Kim YN, Lee DK. Effects of horse-riding exercise on balance, gait, and activities of daily living in stroke patients. *J Phys Ther Sci.* (2015) 27:607–9. doi: 10.1589/jpts.27.607

61. Verheyden G, Vereeck L, Truijen S, Troch M, LaFosse C, Saeys W, et al. Additional exercises improve trunk performance after stroke: a pilot randomized controlled trial. *Neurorehabil Neural Repair.* (2009) 23:281–6. doi: 10.1177/1545968308321776